<DOC>
	<DOC>NCT00244426</DOC>
	<brief_summary>Evaluate efficacy and safety of Indobufen v. Aspirin in preventing thromboembolic events in patients at high risk of CV events such as patients suffering from nonrheumatic atrial fibrillation.</brief_summary>
	<brief_title>S.I.F.A. II: Prevention Of Thromboembolic Events In Patients With Nonrheumatic Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Indobufen</mesh_term>
	<criteria>Chronic or paroxysmal non rheumatic atrial fibrillation with cardioembolic risk factors: hypertension, ischemic cardiopathy, Congestive Heart Failure, diabetes mellitus Clinically relevant organ disease creatinine clearance &lt; 30 ml/min gastric or duodenal ulcer severe anaemia or poliglobulia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Prevention of thromboembolic events in patients with non valvular atrial fibrillation</keyword>
</DOC>